
Winklevoss-Backed Zcash Treasury Company Loses $37.8 Million, Pivots to Cancer Drugs?
Author: Protos
Translation: TechFlow
TechFlow Insight: The market cap of the Winklevoss-backed Zcash (ZEC) treasury company is less than half of its holdings; now it must rely on anti-cancer drugs to tell a new story. This exposes the plight of universal discounting faced by publicly listed crypto companies, and reminds ZEC investors to pay attention to company financing risks.
Winklevoss-backed Zcash (ZEC) treasury company Cypherpunk Technologies announced plans to shift focus to its anti-cancer candidate drug. Previously, the company reported a net loss of $37.8 million in the first half of 2026.
The company admitted that unless ZEC prices rebound soon, it will need to raise significant funds to pay for upcoming FDA trials.
The company predicted today: "We expect to continue generating operating losses in the foreseeable future."
Cypherpunk holds ZEC worth approximately $157 million, but Nasdaq traders value the entire company at only $74 million.
This equals 0.47 times the net asset value multiple (mNAV). It is not surprising that crypto treasury stocks continue to trade below their holdings value.
If pre-funded warrants and other sweeteners are included in the company's claimed enterprise value mNAV, the multiple on the homepage rises to 0.96 times—but still below its ZEC holdings value.

Figure: Cypherpunk Technologies five-year stock price chart. Source: TradingView
Backed by Cameron and Tyler Winklevoss
Cameron and Tyler Winklevoss are the billionaires who helped build the company's ZEC brand.
Initially, the company was successful, acquiring ZEC at an average buy-in price of $341.84—far below the current market price of ZEC at $486.
The company's stock touched $3.70 last November and has now fallen back to below $0.69 per share.
Cypherpunk has lost tens of millions of dollars this year, yet is still planning an expensive FDA trial path for its anti-cancer drug. The stock has fallen 40% this year and 96% over the past five years.
Gemini, the exchange controlled by the Winklevoss twins, is the custodian of the company's ZEC.
Anti-cancer Trials Burn More Cash, ZEC Can't Help
Cypherpunk's anti-cancer candidate drug is the anti-DKK1 antibody Sirexatamab. In a randomized Phase 2 study, it failed to beat the control group in progression-free survival for all patients.
The company attributed this to insufficient power in the final analysis.
On the digital asset treasury business side, ZEC prices were flat within the year, so it didn't help either.
The FDA still granted Fast Track designation to the candidate drug in May, a qualification that accelerates regulatory review. The regulator also agreed to a Phase 3 trial protocol for colorectal cancer with approximately 270 patients.
Onsi stated that the company is "conducting a strategic process to determine the best path forward for sirexatamab: whether as an independently financed spin-off company, or advancing with partners equally committed to cancer patients."
Simply put, this candidate drug needs more money.
Tyler Winklevoss wrote at launch: "We plan to continue accumulating ZEC rapidly, letting Cypherpunk hold at least 5% of ZEC's total supply."
Nine months later, the company now holds 323,394 ZEC, accounting for 1.92% of the circulating supply.
As of June 30, the company had only $7.6 million in cash and cash equivalents, $500 million in accumulated deficit, a continuously loss-making business, and an expensive path for an idealized drug towards FDA approval.















